Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Marcador urinario para la detección del cáncer de vejiga

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TODE20181106001
Publicado:
15/11/2018
Caducidad:
16/11/2019
Resumen:
Un instituto de investigación bávaro ha desarrollado un marcador urinario para la detección del cáncer urotelial de vejiga (CUV). El biomarcador se basa en la proteína de adhesión local LIM y en la proteína SH3 (LASP)-1, implicada en numerosos procesos biológicos y patológicos y que ha sido relacionada con la oncogénesis del cáncer de vejiga. La proteína se detecta en el sedimento de orina evacuado del paciente de cáncer y se describe como un nuevo marcador prometedor para detectar el cáncer urotelial de vejiga. El instituto busca una empresa para continuar con la validación clínica y lanzar la tecnología al mercado. El objetivo es establecer acuerdos de cooperación en materia de investigación, cooperación técnica y licencia.

Details

Tittle:
Urinary marker for bladder cancer detection
Summary:
At a Bavarian Research Institute in the South of Germany a new biomarker for the detection of urothelial bladder cancer (UCB) has been developed. The biomarker is based on a focal adhesion protein and is detected in voided urine sediment of patients. The inventors are now looking for company support for further clinical validation and to bring the marker into the market. They want to enter into a research cooperation -, technical cooperation - and license agreement.
Description:
Urothelial carcinoma of the bladder (UCB) is the most common genitourinary cancer. Diagnosis of UCB currently relies on cystoscopy and urine cytology. Both examination methods have limitations. Urethrocystoscopy is expensive, invasive, and associated with postcystoscopy pain and/or risk of urinary infection. Cystoscopy has tendency to miss flat lesions, such as carcinoma in situ, while urine cytology is prone to missing well-differentiated low-grad lesions. Due to the high recurrence rate patients require regular follow-up examinations, currently done by cystoscopy.
The new biomarker developed at a Bavarian Research Institute is based on the focal adhesion protein LIM and SH3 (LASP)-1 protein which is involved in numerous biological and pathological processes and has been linked to the oncogenesis of bladder cancer. The protein is detected in voided urine sediment of bladder cancer patients and is described as a promising new marker to detect UCB that overcomes the limitations of the current diagnostic tests.
For further clinical validation of this method a research cooperation - or technical cooperation agreement are sought. Furthermore it is planned to bring this marker into the market, therefore they want to enter into a license agreement.
Advantages and Innovations:
· Convenient marker for detection and especially follow-up examination of UCB
· Simply detectable in spontaneously voided urine
· Patient-friendly (non-invasive)
· Strong IP position (granted patents in the 4 main markets)
· Combinable with a second marker to further raise specificity/sensitivity
Stage of Development:
Under development/lab tested
IPs:
Granted patent or patent application essential
CommeR Statunts Regarding IPR Status:
Strong IP Position (granted patents in the 4 main markets EP, US, AU, NZ)
PCT application filed 2012

Partner sought

Type and Role of Partner Sought:
To bring the biomarker to the market it needs to be further clinically validated. Therefore the inventors are looking for support by a company with flexibility regarding the partnership/agreement.

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
German

Keywords

Technology Keywords:
06001005 Diagnósticos, diagnosis